High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy

por Istaiti, Majdolen, Frydman, Dafna, Dinur, Tama, Szer, Jeff, Revel-Vilk, Shoshana, Zimran, Ari
Publicado 2023

Brain-Derived Neurotrophic Factor (BDNF) Is Associated with Platelet Activity and Bleeding Tendency in Patients with Gaucher Disease

por Azoulay, David, Naamad, Mira, Frydman, Dafna, Broide, Ellen, Zimran, Ari, Stemer, Galia, Revel-Vilk, Shoshana
Publicado 2022

Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease

por Dinur, Tama, Istaiti, Majdolen, Frydman, Dafna, Becker-Cohen, Michal, Szer, Jeff, Zimran, Ari, Revel-Vilk, Shoshana
Publicado 2020